CombiMatrix Test Discriminates Malignant Melanoma from Benign Moles
Test uses company’s CustomArray platform.!--h2>
CombiMatrix Molecular Diagnostics launched a new test that discriminates malignant melanoma from benign moles. The test based on CombiMatrix’ CustomArray® platform, enables pathologists to resolve difficult-to-diagnose cases through an objective genetic analysis.
“This exciting new test represents a breakthrough in the field of dermatology,” says Scott Binder, M.D., a member of the company’s scientific advisory board. “As a dermatopathologist I am often called upon to make very difficult decisions regarding whether or not a patient has malignant melanoma, particularly after traditional laboratory methods have failed to provide a clear diagnosis. This test from CombiMatrix molecular diagnostics provides me with a powerful new tool to help resolve many of these tough cases.”